Olympic legend Sir Chris Hoy reveals heath update in prostate...

Olympic legend Sir Chris Hoy reveals heath update in prostate...

SIR Chris Hoy has vowed to fight his stage four prostate cancer and still has hope for the future. The six time Olympic gold medalist has “15...

FDA Approves Gozellix for Advanced PSMA-PET Imaging in Prostate Cancer

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.

PSMA PET Prep Product Gozellix Garners FDA Approval

Indicated for use in cases involving suspected metastasis with PCa or suspected PCa recurrence due to elevated PSA level, Gozellix reportedly has a longer shelf life than other gallium-based PET imaging products.

FDA OKs TLX007-CDx in Prostate Cancer Treatment

TLX007-CDx is now an FDA-approved PSMA PET imaging agent in prostate cancer.

FDA Approves PSMA PET Imaging Agent TLX007-CDx for Prostate Cancer

The FDA has approved TLX007-CDx as an imaging agent in select patients with prostate cancer.

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Melbourne (Australia) | 21 March 2025 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET imaging[1] agent for prostate cancer. Gozellix®, after radiolabeling with 68Ga, is indicated for PET scanning of PSMA positive lesions in men with pro…